Format

Send to

Choose Destination
Curr Opin Biotechnol. 2008 Dec;19(6):608-12. doi: 10.1016/j.copbio.2008.09.001. Epub 2008 Nov 5.

Bacteriophage therapy--cooked goose or phoenix rising?

Author information

1
University of Strathclyde, Strathclyde Institute of Pharmacy and Biomedical Sciences, Royal College Building, 204 George Street, Glasgow G1 1XW, Scotland, UK. m.mattey@strath.ac.uk

Abstract

Recent animal and human trials of bacteriophage therapy have demonstrated its potential to alleviate bacterial diseases, both in internal and in external applications. The regulatory requirements are becoming clearer as more examples are presented. A core of GLP (Good Laboratory Practice) studies will be needed to validate safety and clinical trials to validate efficacy. GMP (Good Manufacturing Practice) production requirements and quality issues will mean that comparable costs to the production of conventional antibiotics should be anticipated. The definition of the 'active substance' will be central to the success of bacteriophage therapy to ensure that the variety and evolutionary potential of bacteriophages are exploited.

PMID:
18926909
DOI:
10.1016/j.copbio.2008.09.001
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Strathprints - the University of Strathclyde
Loading ...
Support Center